Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT05535946 is registered in ClinicalTrials.gov with Abivax S.A. as lead sponsor.

NCT NCT05535946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05535946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Abivax S.A.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 16, 2023
Completion date
May 31, 2030
Enrollment
1,116 (actual)
Sites
413

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis